Business
Marina Biotech to Introduce Its Therapeutic Microbiome Programs Against Gastrointestinal Diseases
Marina Biotech to Introduce Its Therapeutic Microbiome Programs Against Gastrointestinal Diseases.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n \n \n Marina Biotech to Introduce Its Therapeutic Microbiome Programs Against Gastrointestinal Diseases\n \n \nMarina Biotech to Introduce Its Therapeutic Microbiome Programs Against Gastrointestinal Diseases\n \n CITY OF INDUSTRY, CA--(Marketwired - May 30, 2017) - Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that it will be presenting two poster presentations at the 22nd Annual Meeting of the RNA Society being held from May 30 to June 3, 2017, in Prague, Czech Republic, at the Prague Congress Center.\n Dr. Larn Hwang, CSO, is leading the development of Marina Biotech's therapeutic microbiome against FAP and IBD. Marina's patent portfolio around bacterial mediated gene delivery (tkRNAi) and the core of its therapeutic microbiome platform includes 14 issued patents worldwide covering multiple targets including Ras, APC, HER-2, MDR-I, MDR-2, FATP4, SGLUT-1, GLUT-2, GLUT-5, apobec-1, MTP, IL-6, IL-6R, IL-7, IL-12, IL-13, Ra-I, IL-18, p38/JNK MAP kinase, p65/NK-kB, CCL20, Claudin-2, Chitinase 3-like 1, apoA-IV, MHC class I and MHC class II. Clinical and preclinical proof of concept of Marina Biotech's therapeutic microbiome will be presented at the following times:\n Title: tkRNAi-mediated β-catenin knockdown in the Gastrointestinal Mucosa Familial Adenomatous Polyposis\n Patients. Results of START-FAP trial. \n Authors: Larn Hwang, Kevin Ng, Osmond D'Cruz, Sanjive Qazi, Wen Wang, David Nam, Joseph Ramelli, Falguni Trieu, Mihir Munsif, Annie Fong. \n Presenter: Dr. Larn Hwang, CSO, Marina Biotech\n Abstract Number: 644\n Time: Wednesday, May 31st, 20:30 - 23:00\n Title: Preclinical Proof of Concept for Treatment for Inflammatory Bowel Disease (IBD) with Bacterial Delivery of Therapeutic Short Interfering RNAs (siRNAs). \n Authors: Osmond D'Cruz, Kevin Ng, Wen Wang, David Nam, Joseph Ramelli, Falguni Trieu, Mihir Munsif, Larn Hwang.\n Presenter: Dr. Larn Hwang, CSO, Marina Biotech\n Abstract Number: 643\n Time: Friday, June 2nd, 20:30 - 23:00\n About Marina Biotech\n Marina Biotech is a biotechnology company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer. Our ...